Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit

Francis Bessière; Hugo Roccia; Antoine Delinière; Rome Charrière; Philippe Chevalier; Laurent Argaud; Martin Cour

doi:10.1001/jamacardio.2020.1787

Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit

JAMA Cardiol. 2020 Sep 1;5(9):1067-1069. doi: 10.1001/jamacardio.2020.1787.

Authors

Francis Bessière^{1

2}, Hugo Roccia³, Antoine Delinière^{1

2}, Rome Charrière⁴, Philippe Chevalier^{1

2}, Laurent Argaud³, Martin Cour²

Affiliations

¹ Hospices Civils de Lyon, Hôpital Cardiologique Louis Pradel, Service d'électrophysiologie et de Stimulation Cardiaque, Université de Lyon, Lyon, France.
² Hospices Civils de Lyon, Hôpital Cardiologique Louis Pradel, Centre de Référence National des Troubles du Rythme Cardiaque d'origine Héréditaire, Lyon, France.
³ Hospices Civils de Lyon, Hôpital Edouard Herriot, Médecine Intensive - Réanimation, Lyon, France.
⁴ Centre Hospitalier de Valence, Service de Maladies Infectieuses, Valence, France.

Abstract

This case series assesses QT intervals for French patients with coronavirus disease 2019 (COVID-19) treated with hydroxychloroquine alone or in combination with azithromycin.

MeSH terms

Aged
Anti-Bacterial Agents / therapeutic use
Antimalarials / therapeutic use
Azithromycin / therapeutic use*
Betacoronavirus*
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / drug therapy*
Critical Care
Drug Therapy, Combination
Female
Humans
Hydroxychloroquine / therapeutic use*
Long QT Syndrome / diagnosis
Long QT Syndrome / epidemiology*
Male
Middle Aged
Pandemics
Pneumonia, Viral / drug therapy*
Retrospective Studies
SARS-CoV-2

Substances

Anti-Bacterial Agents
Antimalarials
Hydroxychloroquine
Azithromycin